Moore Kuehn Encourages CWBR, RXDX, RUTH, and APGN Investors to Contact Law Firm
25. Mai 2023 11:51 ET
|
Moore Kuehn
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages RXDX, STSA, CHRA, and BLU Investors to Contact Law Firm
18. April 2023 11:32 ET
|
Moore Kuehn
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
28. Februar 2023 16:00 ET
|
Prometheus Biosciences
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – ...
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
07. Dezember 2022 07:00 ET
|
Prometheus Biosciences
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all...
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
09. November 2022 16:01 ET
|
Prometheus Biosciences
- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position...
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
11. August 2022 16:00 ET
|
Prometheus Biosciences
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging...
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
08. Juni 2022 08:00 ET
|
Prometheus Biosciences
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - -...
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
26. Mai 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
12. Mai 2022 16:01 ET
|
Prometheus Biosciences
- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - -...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
30. März 2022 08:00 ET
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...